These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 11493225

  • 1. Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine.
    Sigurdardóttir GR, Nilsson C, Odin P, Grabowski M.
    Acta Neurol Scand; 2001 Aug; 104(2):92-6. PubMed ID: 11493225
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine.
    Merello M, Pirtosek Z, Bishop S, Lees AJ.
    Clin Auton Res; 1992 Aug; 2(4):215-9. PubMed ID: 1392539
    [Abstract] [Full Text] [Related]

  • 3. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST, Woodward WR, Nutt JG.
    Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
    [Abstract] [Full Text] [Related]

  • 4. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004 Feb; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 5. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
    Drapier S, Vérin M.
    Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
    [Abstract] [Full Text] [Related]

  • 6. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J, Merims D, Kuritzky A, Ziv I, Melamed E.
    Harefuah; 1999 Nov 15; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [Abstract] [Full Text] [Related]

  • 7. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
    Ferraz HB, Azevedo-Silva SM, Borges V, Rocha MS, Andrade LA.
    Arq Neuropsiquiatr; 1995 Jun 15; 53(2):245-51. PubMed ID: 7487531
    [Abstract] [Full Text] [Related]

  • 8. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
    van Laar T, Postma AG, Drent M.
    Parkinsonism Relat Disord; 2010 Jan 15; 16(1):71-2. PubMed ID: 19524477
    [No Abstract] [Full Text] [Related]

  • 9. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
    Tison F, Wiart L, Guatterie M, Fouillet N, Lozano V, Henry P, Barat M.
    Mov Disord; 1996 Nov 15; 11(6):729-32. PubMed ID: 8914103
    [Abstract] [Full Text] [Related]

  • 10. Blood pressure effects of apomorphine and domperidone in parkinsonism.
    Pollak P, Mallaret M, Gaio JM, Hommel M, Perret J.
    Adv Neurol; 1987 Nov 15; 45():263-6. PubMed ID: 3548261
    [No Abstract] [Full Text] [Related]

  • 11. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B, Domzał T.
    Neurol Neurochir Pol; 1999 Nov 15; 33(6):1297-303. PubMed ID: 10791032
    [Abstract] [Full Text] [Related]

  • 12. [Improvement in swallowing difficulties treated by subcutaneous apomorphine infusion after deep brain stimulation in Parkinson's disease].
    Bailbé M, Bataille B, Paquereau J, Lavazais S, Vandermarcq P, Gil R.
    Rev Neurol (Paris); 2004 Mar 15; 160(3):352-3. PubMed ID: 15037851
    [Abstract] [Full Text] [Related]

  • 13. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M, Moreau C, Salleron J, Devos D, Kreisler A, Mutez E, Simonin C, Annic A, Dujardin K, Destée A, Defebvre L.
    Rev Neurol (Paris); 2014 Mar 15; 170(3):205-15. PubMed ID: 24594365
    [Abstract] [Full Text] [Related]

  • 14. Apomorphine in the treatment of Parkinson's disease.
    Hagell P, Odin P.
    J Neurosci Nurs; 2001 Feb 15; 33(1):21-34, 37-8. PubMed ID: 11233359
    [Abstract] [Full Text] [Related]

  • 15. [Apomorphine in the treatment of Parkinson's Disease].
    Dressler D.
    Nervenarzt; 2005 Jun 15; 76(6):681-9. PubMed ID: 15592807
    [Abstract] [Full Text] [Related]

  • 16. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ, Sesar-Ignacio Á.
    Rev Neurol; 2012 Jun 15; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [Abstract] [Full Text] [Related]

  • 17. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 Jun 15; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of Prescription Practices of Domperidone in Parkinson's Disease: A Cross Sectional Study Among French Neurologists.
    Lastennet D, Mariani LL, Rascol O, Turc JD, Alfaisal H, Lapeyre-Mestre M, Corvol JC, Tubach F.
    CNS Drugs; 2020 Dec 15; 34(12):1267-1274. PubMed ID: 33278018
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous apomorphine in parkinsonian on-off oscillations.
    Stibe CM, Lees AJ, Kempster PA, Stern GM.
    Lancet; 1988 Feb 20; 1(8582):403-6. PubMed ID: 2893200
    [Abstract] [Full Text] [Related]

  • 20. Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone.
    Gálvez-Jiménez N, Lang AE.
    Can J Neurol Sci; 1996 Aug 20; 23(3):198-203. PubMed ID: 8862842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.